Li Chong, He Anqi, Hu Jing, Xia Yong, He Chengqi, Zhuang Weihua
Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, China.
Key Laboratory of Rehabilitation Medicine in Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
Transl Lung Cancer Res. 2024 Dec 31;13(12):3764-3777. doi: 10.21037/tlcr-24-653. Epub 2024 Dec 27.
BACKGROUND AND OBJECTIVE: While bibliometric studies of single journals have been conducted, bibliometric mapping has not yet been used to analyze the literature published by the (). This study aimed to comprehensively review all publications of from its inception to 2024 and provide a detailed overview of its main publication characteristics. METHODS: This study analyzed publications from spanning 2012 to 2024 using CiteSpace, VOSviewer, and the 'Bibliometrix' package in R. Descriptive bibliometric methods were employed to examine the trends and dynamics in literature, identifying leading authors, institutions, and countries in terms of publication output. Furthermore, bibliometric maps were generated to visualize key research topics and terms, highlighting their evolution over time. KEY CONTENT AND FINDINGS: The analysis included 2,032 publications in from 2012 to 2023 and 121 publications in 2024. The study revealed a positive trend in literature production, although there has been a slight recent decline in the number of articles published in the . China emerged as the most productive country (n=587), with Shanghai Jiao Tong University being the most productive institution (n=127). Jianxing He from the First Affiliated Hospital of Guangzhou Medical University was identified as the most prolific author (n=75). The top ten most cited articles primarily address treatment strategies, recurrence, immune-related toxicities, global trends in mortality, and mechanisms of resistance, reflecting the broad scope and critical importance of ongoing research in lung cancer. Research published in predominantly targeted old adults with non-small cell lung cancer (n=879), with significant emphasis on overall survival (n=507), cancer staging (n=406), and cancer immunotherapy. CONCLUSIONS: This study reviewed publications from 2012 to 2024, identifying key trends, top contributors, and research focuses. Future research directions in might focus on first-line treatment, ensartinib, and advanced data analysis methods such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) to revolutionize lung cancer research and practice. In conclusion, this study underscores 's significant contributions to lung cancer research and provides valuable insights into its evolution and future directions.
背景与目的:虽然已对单一期刊进行了文献计量学研究,但文献计量学图谱尚未用于分析()发表的文献。本研究旨在全面回顾从创刊到2024年的所有出版物,并详细概述其主要出版特征。 方法:本研究使用CiteSpace、VOSviewer和R中的“Bibliometrix”软件包分析了2012年至2024年期间的出版物。采用描述性文献计量学方法研究文献的趋势和动态,确定在发表量方面领先的作者、机构和国家。此外,生成文献计量学图谱以可视化关键研究主题和术语,突出它们随时间的演变。 关键内容与发现:分析包括2012年至2023年期间该期刊的2032篇出版物以及2024年的121篇出版物。研究显示文献产出呈积极趋势,尽管该期刊最近发表的文章数量略有下降。中国成为产出最多的国家(n = 587),上海交通大学是产出最多的机构(n = 127)。广州医科大学第一附属医院的何建行被确定为发文量最多的作者(n = 75)。被引用次数最多的前十篇文章主要涉及治疗策略、复发、免疫相关毒性、全球死亡率趋势以及耐药机制,反映了肺癌当前研究的广泛范围和至关重要性。该期刊发表的研究主要针对老年非小细胞肺癌患者(n = 879),重点关注总生存期(n = 507)、癌症分期(n = 406)和癌症免疫治疗。 结论:本研究回顾了2012年至2024年期间的出版物,确定了关键趋势、主要贡献者和研究重点。该期刊未来的研究方向可能集中在一线治疗、恩沙替尼以及诸如京都基因与基因组百科全书(KEGG)等先进数据分析方法上,以革新肺癌研究与实践。总之,本研究强调了该期刊对肺癌研究的重大贡献,并为其发展演变及未来方向提供了有价值的见解。
Transl Lung Cancer Res. 2024-12-31
Heliyon. 2024-12-16
Front Endocrinol (Lausanne). 2023
Front Cell Infect Microbiol. 2022
Front Immunol. 2023
Transl Lung Cancer Res. 2024-9-30
Transl Lung Cancer Res. 2023-11-30
Community Dent Oral Epidemiol. 2024-4
Transl Lung Cancer Res. 2023-7-31